Potential impacts of GLP-1 drugs should be considered as key risks to Resmed investment thesis. However, the likely impact is overstated, or over-priced into the share price. Resmed is trading at 18 times their FY25 forecast compared to the 10-year average of 28 times.
Buy RMD now and get great upside returns in a year or two, page-6
-
- There are more pages in this discussion • 192 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$33.02 |
Change
0.360(1.10%) |
Mkt cap ! $21.35B | |||
| Open | High | Low | Value | Volume |
| $32.95 | $33.23 | $32.89 | $9.700M | 293.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1028 | $33.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $33.04 | 1812 | 11 |
View Market Depth
| Last trade - 12.26pm 12/08/2024 (20 minute delay) ? |
| RMD (ASX) Chart |